Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 1.230

-2.4%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	11/3/2014 10:47:04 AM
	of 3576

Geron Corp.'s stock (GERN) soared 35% in premarket trade Monday, after the company said the Food and Drug Administration lifted its hold on the investigational new drug application for its cancer treatment imetelstat. Geron added that the FDA also accepted its development plan for imetelstat. The company now expects to start a Phase 2 clinical trial of imetelstat focused on high-risk myeloid malignancies in the first half of 2015. Geron's stock had dropped 50% so far this year through Friday, while the iShares Nasdaq Biotechnology ETF (IBB) has climbed 31% and the S&P 500 (SPX) has gained 9.2%.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next